An overview of clinical and commercial impact of drug delivery systems.
An overview of clinical and commercial impact of drug delivery systems.
复制标题
药物输送系统的临床和商业影响概述。
DOI：
10.1016/j.jconrel.2014.03.053
复制
发表时间：
2014-09-28
期刊：
影响因子：
--
通讯作者：
Mitragotri S
中科院分区：
文献类型：
--
作者：
Anselmo AC;Mitragotri S
为了改善药物化合物和分子的输送，药物输送系统得到了广泛的研究和开发。在过去的几十年里，由于研究人员、研究资金、风险资本和初创企业数量的增加，该领域得到了显著的发展。总的来说，这种增长导致了利用微/纳米颗粒、透皮贴片、吸入器、药物储存库植入物和抗体-药物偶联物的新系统的出现。虽然研究活动的增加明显表明该领域的扩散，但早期研究思想的临床和商业转化对该领域的未来增长和兴趣至关重要。在这里，我们将重点介绍一些经过这种翻译的新型药物输送系统的例子。具体来说，我们将讨论以下方面的发展、优势、局限性和经验教训：(i)基于微粒的储存制剂，（ii）基于纳米颗粒的抗癌药物，（iii）透皮系统，（iv）口服给药系统，(v)肺给药系统，（vi）植入物和（vii）抗体-药物偶联物。这些系统影响了许多流行疾病的治疗，包括糖尿病、癌症和心血管疾病等。同时，这些系统是产品不可或缺的组成部分，这些产品的年收入总和超过1000亿美元。这些例子为药物输送系统的临床和商业影响提供了强有力的证据。
Drug delivery systems are widely researched and developed to improve the delivery of pharmaceutical compounds and molecules. The last few decades have seen a marked growth of the field fueled by increased number of researchers, research funding, venture capital and the number of start-ups. Collectively, the growth has led to novel systems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conjugates. While the increased research activity is clearly an indication of proliferation of the field, clinical and commercial translation of early-stage research ideas is critically important for future growth and interest in the field. Here, we will highlight some of the examples of novel drug delivery systems that have undergone such translation. Specifically, we will discuss the developments, advantages, limitations and lessons learned from: (i) microparticle-based depot formulations, (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi) implants and (vii) antibody-drug conjugates. These systems have impacted treatment of many prevalent diseases including diabetes, cancer and cardiovascular diseases, among others. At the same time, these systems are integral and enabling components of products that collectively generate annual revenues exceeding US $100 billion. These examples provide strong evidence of the clinical and commercial impact of drug delivery systems.
登录
查看更多内容
影响因子：
4.8
作者：
Dalby, B;Cates, S;Ciccarone, VC
通讯作者：
Ciccarone, VC
影响因子：
3.7
作者：
Daddona, Peter E.;Matriano, James. A.;Maa, Yuh-Fun
通讯作者：
Maa, Yuh-Fun
影响因子：
4.7
作者：
ASHBURN, MA;STEPHEN, RL;HOFMAN, AA
通讯作者：
HOFMAN, AA
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
5.8
作者：
Arora, Anubhav;Prausnitz, Mark R.;Mitragotri, Samir
通讯作者：
Mitragotri, Samir